NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:NMR • US65535H2085

9.42 USD
+0.06 (+0.64%)
At close: Feb 11, 2026
9.4 USD
-0.02 (-0.21%)
Pre-Market: 2/12/2026, 7:53:39 AM
Fundamental Rating

3

NMR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 238 industry peers in the Capital Markets industry. Both the profitability and financial health of NMR have multiple concerns. NMR is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year NMR was profitable.
  • NMR had a positive operating cash flow in the past year.
  • NMR had positive earnings in each of the past 5 years.
  • In multiple years NMR reported negative operating cash flow during the last 5 years.
NMR Yearly Net Income VS EBIT VS OCF VS FCFNMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B 1T -1T -1.5T

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.61%, NMR is doing worse than 71.85% of the companies in the same industry.
  • NMR's Return On Equity of 10.62% is fine compared to the rest of the industry. NMR outperforms 62.18% of its industry peers.
  • NMR has a Return On Invested Capital of 0.68%. This is in the lower half of the industry: NMR underperforms 66.81% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for NMR is significantly below the industry average of 7.22%.
  • The last Return On Invested Capital (0.68%) for NMR is above the 3 year average (0.42%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROIC 0.68%
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
NMR Yearly ROA, ROE, ROICNMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • The Profit Margin of NMR (8.05%) is worse than 66.39% of its industry peers.
  • NMR's Profit Margin has declined in the last couple of years.
  • With a Operating Margin value of 11.60%, NMR is not doing good in the industry: 63.03% of the companies in the same industry are doing better.
  • NMR's Operating Margin has declined in the last couple of years.
  • With a Gross Margin value of 43.38%, NMR perfoms like the industry average, outperforming 45.80% of the companies in the same industry.
  • NMR's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
NMR Yearly Profit, Operating, Gross MarginsNMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

1

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, NMR has less shares outstanding
  • Compared to 5 years ago, NMR has less shares outstanding
  • The debt/assets ratio for NMR has been reduced compared to a year ago.
NMR Yearly Shares OutstandingNMR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
NMR Yearly Total Debt VS Total AssetsNMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10T 20T 30T 40T 50T

2.2 Solvency

  • NMR has an Altman-Z score of -0.22. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
  • NMR has a worse Altman-Z score (-0.22) than 80.25% of its industry peers.
  • NMR has a Debt/Equity ratio of 10.65. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 10.65, NMR is doing worse than 87.39% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Altman-Z -0.22
ROIC/WACCN/A
WACCN/A
NMR Yearly LT Debt VS Equity VS FCFNMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5T 10T

2.3 Liquidity

  • NMR has a Current Ratio of 0.27. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.27, NMR is doing worse than 81.51% of the companies in the same industry.
  • A Quick Ratio of 0.27 indicates that NMR may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.27, NMR is doing worse than 81.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.27
Quick Ratio 0.27
NMR Yearly Current Assets VS Current LiabilitesNMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T 20T 25T

3

3. Growth

3.1 Past

  • NMR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.84%, which is quite good.
  • Measured over the past years, NMR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.96% on average per year.
  • The Revenue has decreased by -4.21% in the past year.
  • Measured over the past years, NMR shows a quite strong growth in Revenue. The Revenue has been growing by 19.39% on average per year.
EPS 1Y (TTM)9.84%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-9.14%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%2.5%

3.2 Future

  • Based on estimates for the next years, NMR will show a small growth in Earnings Per Share. The EPS will grow by 3.79% on average per year.
  • Based on estimates for the next years, NMR will show a decrease in Revenue. The Revenue will decrease by -5.88% on average per year.
EPS Next Y10.55%
EPS Next 2Y3.07%
EPS Next 3Y3.79%
EPS Next 5YN/A
Revenue Next Year-18.17%
Revenue Next 2Y-9.64%
Revenue Next 3Y-5.88%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NMR Yearly Revenue VS EstimatesNMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
NMR Yearly EPS VS EstimatesNMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 100

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 11.49, which indicates a very decent valuation of NMR.
  • 60.50% of the companies in the same industry are more expensive than NMR, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 28.18, NMR is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 11.53, the valuation of NMR can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 62.60% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.01. NMR is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.49
Fwd PE 11.53
NMR Price Earnings VS Forward Price EarningsNMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 68.07% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.5
NMR Per share dataNMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • NMR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.09
PEG (5Y)1.05
EPS Next 2Y3.07%
EPS Next 3Y3.79%

5

5. Dividend

5.1 Amount

  • NMR has a Yearly Dividend Yield of 3.54%.
  • Compared to an average industry Dividend Yield of 6.12, NMR has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.80, NMR pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.54%

5.2 History

  • On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
  • NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
  • NMR has decreased its dividend in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
NMR Yearly Dividends per shareNMR Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

5.3 Sustainability

  • 45.53% of the earnings are spent on dividend by NMR. This is a bit on the high side, but may be sustainable.
  • NMR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP45.53%
EPS Next 2Y3.07%
EPS Next 3Y3.79%
NMR Yearly Income VS Free CF VS DividendNMR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B -1T -1.5T
NMR Dividend Payout.NMR Dividend Payout, showing the Payout Ratio.NMR Dividend Payout.PayoutRetained Earnings

NOMURA HOLDINGS INC-SPON ADR

NYSE:NMR (2/11/2026, 8:04:00 PM)

Premarket: 9.4 -0.02 (-0.21%)

9.42

+0.06 (+0.64%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)02-10
Earnings (Next)07-27
Inst Owners41.8%
Inst Owner Change0.77%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap27.64B
Revenue(TTM)4.63T
Net Income(TTM)370.05B
Analysts72.31
Price Target8.31 (-11.78%)
Short Float %0.06%
Short Ratio1.33
Dividend
Industry RankSector Rank
Dividend Yield 3.54%
Yearly Dividend0.26
Dividend Growth(5Y)15.59%
DP45.53%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-4.65%
Max EPS beat(2)22.4%
EPS beat(4)2
Avg EPS beat(4)16.43%
Min EPS beat(4)-10.21%
Max EPS beat(4)58.19%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.01%
PT rev (3m)7.52%
EPS NQ rev (1m)-7.97%
EPS NQ rev (3m)29.24%
EPS NY rev (1m)0.86%
EPS NY rev (3m)4.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.53%
Valuation
Industry RankSector Rank
PE 11.49
Fwd PE 11.53
P/S 0.92
P/FCF N/A
P/OCF 6.7
P/B 1.22
P/tB 1.25
EV/EBITDA 21.5
EPS(TTM)0.82
EY8.7%
EPS(NY)0.82
Fwd EY8.67%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)1.41
OCFY14.92%
SpS10.2
BVpS7.73
TBVpS7.57
PEG (NY)1.09
PEG (5Y)1.05
Graham Number11.95
Profitability
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROCE 1.68%
ROIC 0.68%
ROICexc 0.76%
ROICexgc 0.77%
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
FCFM N/A
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score7
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Debt/EBITDA 62.4
Cap/Depr 1450.41%
Cap/Sales 19.46%
Interest Coverage 0.21
Cash Conversion 106.5%
Profit Quality N/A
Current Ratio 0.27
Quick Ratio 0.27
Altman-Z -0.22
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.84%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-9.14%
EPS Next Y10.55%
EPS Next 2Y3.07%
EPS Next 3Y3.79%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%2.5%
Revenue Next Year-18.17%
Revenue Next 2Y-9.64%
Revenue Next 3Y-5.88%
Revenue Next 5YN/A
EBIT growth 1Y31.03%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year26369.3%
EBIT Next 3Y529.26%
EBIT Next 5YN/A
FCF growth 1Y58.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y236.88%
OCF growth 3YN/A
OCF growth 5YN/A

NOMURA HOLDINGS INC-SPON ADR / NMR FAQ

Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?

ChartMill assigns a fundamental rating of 3 / 10 to NMR.


What is the valuation status of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

ChartMill assigns a valuation rating of 5 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.


Can you provide the profitability details for NOMURA HOLDINGS INC-SPON ADR?

NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 3 / 10.


What is the financial health of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

The financial health rating of NOMURA HOLDINGS INC-SPON ADR (NMR) is 1 / 10.


What is the earnings growth outlook for NOMURA HOLDINGS INC-SPON ADR?

The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 10.55% in the next year.